Teikoku Pharma USA and Eisai have entered into a license agreement on the donepezil patch currently being developed in all territories except Japan.
Teikoku Pharma USA, Inc., announced today that it has entered into an agreement with Dermatrends.
Teikoku Pharma annouces that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis® in the UK
In furthering it's strength in transdermal drug delivery, Teikoku signs an agreement with Altea Therapeutics to develop and commercialize a new patch therapy for managing Parkinson's Disease, utilizing Altea Therapeutics' PassPort technology.
Endo Pharmaceuticals has released clinical trial data that found patients receiving either Lidoderm or Celebrex 200 mg for pain...
Teikoku today announced its relocation to San Jose, California.